Schools

Cartwright, D., Kidd, A. C., Ansel, S., Ascierto, M. L., Spiliopoulou, P. (2025) Oncogenic signalling pathways in cancer immunotherapy: leader or follower in this delicate dance? International Journal of Molecular Sciences,

Dobbin, S. J. H., Mangion, K., Berry, C., Roditi, G., Basak, S., McClure, J. D., Brooksbank, K., Sonecki, P., Sourbron, S., Evans, J., White, J., Welsh, P., Butler, E., Venugopal, B., Touyz, R. M., Jones, R. J., Petrie, M. C., Lang, N. N. (2025) Vascular endothelial growth factor inhibitor-induced cardiotoxicity: prospective multimodality assessment incorporating cardiovascular magnetic resonance imaging. Heart, (doi: 10.1136/heartjnl-2024-325535)

Genta, S., Araujo, D.V., Hueniken, K., Pipinikas, C., Ventura, R., Rojas, P., Jones, G., Butler, M.O., Saibil, S.D., Yu, C., Easson, A., Covelli, A., Sauder, M.B., Fournier, C., Saeed Kamil, Z., Rogalla, P., Arteaga, D.P., Vornicova, O., Spiliopoulou, P., Muniz, T.P., Siu, L.L., Spreafico, A. (2024) Bespoke ctDNA for longitudinal detection of molecular residual disease in high-risk melanoma patients. ESMO Open, 9, (doi: 10.1016/j.esmoop.2024.103978)

Spear, S., Le Saux, O., Mirza, H. B., Iyer, N., Tyson, K., Grundland Freile, F., Walton, J. B., Woodman, C., Jarvis, S., Ennis, D. P., Aguirre Hernandez, C., Xu, Y., Spiliopoulou, P., Brenton, J. D., Costa-Pereira, A. P., Cook, D. P., Vanderhyden, B. C., Keun, H. C., Triantafyllou, E., Arnold, J. N., McNeish, I. A. (2024) PTEN loss shapes macrophage dynamics in high grade serous ovarian carcinoma. Cancer Research, (doi: 10.1158/0008-5472.can-23-3890)

Pereira, B. A. et al. (2024) Temporally resolved proteomics identifies nidogen-2 as a cotarget in pancreatic cancer that modulates fibrosis and therapy response. Science Advances, 10, (doi: 10.1126/sciadv.adl1197)

Manchanda, R. et al. (2024) Cost-effectiveness of unselected multigene germline and somatic genetic testing for epithelial ovarian cancer. Journal of the National Comprehensive Cancer Network, 22, (doi: 10.6004/jnccn.2023.7331)

Spiliopoulou, P., Kazmi, F., Aroldi, F., Holmes, T., Thompson, D., Griffiths, L., Qi, C., Parkes, M., Lord, S., Veal, G. J., Harrison, D. J., Coyle, V. M., Graham, J., Jeffry Evans, T. R., Blagden, S. P. (2024) A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301) Journal of Experimental and Clinical Cancer Research, 43, (doi: 10.1186/s13046-024-03010-1)

Dickson, A. L., Zickuhr, G. M., Um, I. H., Zhang, Y., Plummer, R., Blagden, S. P., Symeonides, S. N., Cook, N., Evans, T.R. J., Elshani, M., Harrison, D. J. (2024) Exposing the heterogeneity of the lipidome in the TME of cutaneous melanoma following treatment with NUC-7738 in combination with anti-PD-1 therapy. (doi: 10.1158/1538-7445.am2024-6222)

Sacco, J. J., Jackson, R., Corrie, P., Danson, S., Evans, J., Ochsenreither, S., Kumar, S., Goodman, A., Larkin, J., Karydis, I., Steven, N., Lorigan, P., Plummer, R., Patel, P., Psarelli, E., Olsson-Brown, A., Shaw, H., Leyvraz, S., Handley, L., Rawcliffe, C., Nathan, P. (2024) A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma. European Journal of Cancer, 202, (doi: 10.1016/j.ejca.2024.114009)

Lee, C. L., O'Kane, G. M., Mason, W. P., Zhang, W.-J., Spiliopoulou, P., Hansen, A. R., Grant, R. C., Knox, J. J., Stockley, T. L., Zadeh, G., Chen, E. X. (2024) Circulating oncometabolite 2-hydroxyglutarate (2HG) as a potential biomarker for isocitrate dehydrogenase (IDH1/2) mutant cholangiocarcinoma. Molecular Cancer Therapeutics, 23, pp. 394-399. (doi: 10.1158/1535-7163.mct-23-0460)

Spiliopoulou, P., Kaur, P., Hammett, T., Di Conza, G., Lahn, M. (2024) Targeting T regulatory (Treg) cells in immunotherapy-resistant cancers. Cancer Drug Resistance, 7, (doi: 10.20517/cdr.2023.46)

Spiliopoulou, P., Lopes, C. D. H., Spreafico, A. (2024) Promising and minimally invasive biomarkers: targeting melanoma. Cells, 13, (doi: 10.3390/cells13010019)

Janse van Rensburg, H. J., Spiliopoulou, P., Makhzoum, A., Healy, B. D. (2023) Remitting seronegative symmetrical synovitis with pitting edema: a case report of an immune-related adverse event following surgery. Case Reports in Oncology, 16, pp. 662-669. (doi: 10.1159/000532004)

McLaren, A. S., Spoor, J. A., Cartwright, D., Naylor, G., Barclay, S., Priest, M., Puttagunta, S., Armstrong, K., Ballantyne, S., Stanley, A., Evans, T. R. J., West of Scotland HCC MDT, (2023) Impact of the COVID-19 pandemic on patients with hepatocellular carcinoma in the west of Scotland: a cohort study. BMJ Open Gastroenterology, 10, (doi: 10.1136/bmjgast-2023-001231)

Genta, S., Lajkosz, K., Yee, N. R., Spiliopoulou, P., Heirali, A., Hansen, A. R., Siu, L. L., Saibil, S., Stayner, L.-A., Yanekina, M., Sauder, M. B., Keshavarzi, S., Salawu, A., Vornicova, O., Butler, M. O., Bedard, P. L., Razak, A. R. A., Rottapel, R., Chruscinski, A., Coburn, B., Spreafico, A. (2023) Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT) Journal of Experimental and Clinical Cancer Research, 42, (doi: 10.1186/s13046-023-02851-6)

Kristeleit, R., Plummer, R., Jones, R., Carter, L., Blagden, S., Sarker, D., Arkenau, T., Evans, T. R. J., Danson, S., Symeonides, S. N., Veal, G. J., Klencke, B. J., Kowalski, M. M., Banerji, U. (2023) A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer. British Journal of Cancer, 129, pp. 38-45. (doi: 10.1038/s41416-023-02279-x)

Solovyeva, O., Dimairo, M., Weir, C. J., Hee, S. W., Espinasse, A., Ursino, M., Patel, D., Kightley, A., Hughes, S., Jaki, T., Mander, A., Evans, T. R. J., Lee, S., Hopewell, S., Rantell, K. R., Chan, A.-W., Bedding, A., Stephens, R., Richards, D., Roberts, L., Kirkpatrick, J., de Bono, J., Yap, C. (2023) Development of consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding trials: the DEFINE study. BMC Medicine, 21, (doi: 10.1186/s12916-023-02937-0)

Hamid, O., Hassel, J. C., Shoushtari, A. N., Meier, F., Bauer, T. M., Salama, A. K.S., Kirkwood, J. M., Ascierto, P. A., Lorigan, P. C., Mauch, C., Orloff, M., Evans, T. R. J., Holland, C., Edukulla, R., Abedin, S. E., Middleton, M. R. (2023) Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study. Journal for ImmunoTherapy of Cancer, 11, (doi: 10.1136/jitc-2023-006747)

Mittal, A., Al-Ezzi, E., Li, X., Moloney, B., Wilson, B., Spiliopoulou, P., Sridhar, S., Fallah-Rad, N., Chung, P., James Hamilton, R., O’malley, M., Hansen, A. R. (2023) The role of cytoreductive nephrectomy and systemic therapy in the management of tumour thrombus in patients with metastatic renal cell carcinoma. British Journal of Cancer, 128, pp. 1888-1896. (doi: 10.1038/s41416-023-02166-5)

Espinasse, A., Solovyeva, O., Dimairo, M., Weir, C., Jaki, T., Mander, A., Kightley, A., Evans, J., Lee, S., Bedding, A., Hopewell, S., Rantell, K., Liu, R., Chan, A.-W., De Bono, J., Yap, C. (2023) SPIRIT and CONSORT extensions for early phase dose-finding clinical trials: the DEFINE (DosE-FIndiNg Extensions) study protocol. BMJ Open, 13, (doi: 10.1136/bmjopen-2022-068173)

Spiliopoulou, P., Janse van Rensburg, H. J., Avery, L., Kulasingam, V., Razak, A., Bedard, P., Hansen, A., Chruscinski, A., Wang, B., Kulikova, M., Chen, R., Speers, V., Nguyen, A., Lee, J., Coburn, B., Spreafico, A., Siu, L. L. (2023) Longitudinal efficacy and toxicity of SARS-CoV-2 vaccination in cancer patients treated with immunotherapy. Cell Death and Disease, 14, (doi: 10.1038/s41419-022-05548-4)

Spiliopoulou, P., Vornicova, O., Genta, S., Spreafico, A. (2023) Shaping the future of immunotherapy targets and biomarkers in melanoma and non-melanoma cutaneous cancers. International Journal of Molecular Sciences, 24, (doi: 10.3390/ijms24021294)

Ali, A., Jamieson, N. B., Khan, I. Q., Chang, D., Giovannetti, E., Funel, N., Frampton, A.E., Morton, J., Sansom, O., Evans, T.R.J., Duthie, F., McKay, C. J., Samra, J.S., Gill, A. J., Biankin, A., Oien, K. A. (2022) Prognostic implications of microRNA-21 overexpression in pancreatic ductal adenocarcinoma: an international multicenter study of 686 patients. American Journal of Cancer Research, 12, pp. 5668-5683.

Evans, J., Keith, N., Paul, J. (2022) An analysis of Relative Telomere Length (RTL) during peri-operative chemotherapy in patients with operable gastric or gastro-oesophageal junction adenocarcinoma. (doi: 10.17504/protocols.io.ca5csg2w)

Sala, A., Cameron, J. M., Jenkins, C. A., Barr, H., Christie, L., Conn, J. J.A., Evans, T. R. J., Harris, D. A., Palmer, D. S., Rinaldi, C., Theakstone, A. G., Baker, M. J. (2022) Liquid biopsy for pancreatic cancer detection using infrared spectroscopy. Cancers, 14, (doi: 10.3390/cancers14133048)

Evans, J., Keith, N., Paul, J. (2022) An analysis of Relative Telomere Length (RTL) during chemotherapy in patients with advanced gastro-oesophageal adenocarcinoma. (doi: 10.17504/protocols.io.n92ldznenv5b/v1)

Janse van Rensburg, H. J., Spiliopoulou, P., Siu, L. L. (2022) Circulating biomarkers for therapeutic monitoring of anti-cancer agents. Oncologist, 27, pp. 352-362. (doi: 10.1093/oncolo/oyac047)

Spiliopoulou, P., Yang, S.Y. C., Bruce, J. P., Wang, B. X., Berman, H. K., Pugh, T. J., Siu, L. L. (2022) All is not lost: learning from 9p21 loss in cancer. Trends in Immunology, 43, pp. 379-390. (doi: 10.1016/j.it.2022.03.003)

Spiliopoulou, P., Spear, S., Mirza, H., Garner, I., Iyer, N., McGarry, L., Grundland-Freile, F., Cheng, Z., Ennis, D. P., McNamara, S., Natoli, M., Mason, S., Blyth, K., Adams, P. D., Roxburgh, P., Fuchter, M. J., Brown, B., McNeish, I. A. (2022) Dual G9A/EZH2 inhibition stimulates anti-tumour immune response in ovarian high grade serous carcinoma. Molecular Cancer Therapeutics, 21, pp. 522-534. (doi: 10.1158/1535-7163.MCT-21-0743)

Glen, C., Tan, Y. Y., Waterston, A., Evans, T. R. J., Jones, R. J., Petrie, M. C., Lang, N. N. (2022) Mechanistic and clinical overview cardiovascular toxicity of BRAF and MEK inhibitors: JACC: CardioOncology state-of-the-art review. JACC: CardioOncology, 4, pp. 1-18. (doi: 10.1016/j.jaccao.2022.01.096)

Finn, R. S., Kudo, M., Cheng, A.-L., Wyrwicz, L., Ngan, R. K.C., Blanc, J.-F., Baron, A. D., Vogel, A., Ikeda, M., Piscaglia, F., Han, K.-H., Qin, S., Minoshima, Y., Kanekiyo, M., Ren, M., Dairiki, R., Tamai, T., Dutcus, C. E., Ikezawa, H., Funahashi, Y., Evans, T. R. J. (2021) Pharmacodynamic biomarkers predictive of survival benefit with lenvatinib in unresectable hepatocellular carcinoma: from the phase III REFLECT study. Clinical Cancer Research, 27, pp. 4848-4858. (doi: 10.1158/1078-0432.CCR-20-4219)

Middleton, M. R., Dean, E., Evans, T. R.J., Shapiro, G. I., Pollard, J., Hendriks, B. S., Falk, M., Diaz-Padilla, I., Plummer, R. (2021) Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours. British Journal of Cancer, 125, pp. 510-519. (doi: 10.1038/s41416-021-01405-x)

Spiliopoulou, P., Hinsley, S., Mcneish, I. A., Roxburgh, P., Glasspool, R. (2021) Metronomic oral cyclophosphamide in relapsed ovarian cancer. International Journal of Gynecological Cancer, 31, pp. 1037-1044. (doi: 10.1136/ijgc-2021-002467)

Lei, M., Siemers, N. O., Pandya, D., Chang, H., Sanchez, T., Harbison, C., Szabo, P. M., Janjigian, Y., Ott, P. A., Sharma, P., Bendell, J., Evans, T. R. J., de Braud, F., Chau, I., Boyd1, Z. (2021) Analyses of PD-L1 and inflammatory gene expression association with efficacy of nivolumab±Ipilimumab in gastric cancer/gastroesophageal junction cancer. Clinical Cancer Research, 27, pp. 3926-3935. (doi: 10.1158/1078-0432.CCR-20-2790)

Haq, M. I., Drake, T. M., Goh, T. L., Ahmed, A., Forrest, E., Barclay, S., Gillespie, R., Priest, M., Evans, J., Graham, J., Ballantyne, S., McMillan, D. C., Hayes, P. C., Bird, T. G., Stanley, A. J. (2021) Effect of hepatocellular carcinoma surveillance programmes on overall survival in a mixed cirrhotic UK population: a prospective, longitudinal cohort study. Journal of Clinical Medicine, 10, (doi: 10.3390/jcm10132770)

Welisch, G., Twelves, C., Plummer, R., Evans, J., Danson, S., Symeonides, S., Halsey, C., Jones, R., Hanna, C., Gallagher, P., Walls, G., Taylor, K., Barnett, S., Forde, C., White, M., Williams, C., El Badri, S., Chipole, B.'e. D., Keith, N. (2021) First in Human: who and what makes a cancer phase 1 trial and why are they so important? (doi: 10.17605/OSF.IO/KWHQF)

McNamara, M. G., Bridgewater, J., Palmer, D.H., Faluyi, O., Wasan, H., Patel, A., Ryder, W.D., Barber, S., Gnanaranjan, C., Ghazaly, E., Evans, T.R.J., Valle, J.W. (2021) A phase Ib study of NUC-1031 in combination with cisplatin for the first-line treatment of patients with advanced biliary tract cancer (ABC-08) Oncologist, 26, pp. e669-e678. (doi: 10.1002/onco.13598)

Annese, V. F., Patil, S. B., Hu, C., Giagkoulovits, C., Al-Rawhani, M. A., Grant, J., Macleod, M., Clayton, D.J., Heaney, L.M., Daly, R., Accarino, C., Shah, Y. D., Cheah, B. C., Beeley, J., Evans, T.R.J., Jones, R., Barrett, M. P., Cumming, D. R.S. (2021) A monolithic single-chip point-of-care platform for metabolomic prostate cancer detection. Microsystems and Nanoengineering, 7, (doi: 10.1038/s41378-021-00243-4)

Keith, N., Plummer, R., Coyle, V., Cameron, D., Evans, J., Twelves, C., Palmer, D., Danson, S., Graham, D., Welisch, G. (2021) Early Phase Cancer Research in the COVID-19 Pandemic: an ECMC North Initiative. (doi: 10.17605/OSF.IO/6WTN2)

Middleton, M. R., McAlpine, C., Woodcock, V. K., Corrie, P., Infante, J. R., Steven, N. M., Evans, T. R. J., Anthoney, A., Shoushtari, A. N., Hamid, O., Gupta, A., Vardeu, A., Leach, E., Naidoo, R., Stanhope, S., Lewis, S., Hurstb, J., O’Kelly, I., Sznol, M. (2020) Tebentafusp, a TCR/anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma. Clinical Cancer Research, 26, pp. 5869-5878. (doi: 10.1158/1078-0432.CCR-20-1247)

Kristeleit, R. et al. (2020) Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours. British Journal of Cancer, 123, pp. 1360-1369. (doi: 10.1038/s41416-020-1010-8)

Sarker, D., Plummer, R., Meyer, T., Sodergren, M. H., Basu, B., Chee, C. E., , (2020) MTL-CEBPA, a small activating RNA therapeutic upregulating C/EBP-α, in patients with advanced liver cancer: a first-in-human, multicenter, open-label, phase I trial. Clinical Cancer Research, 26, pp. 3936-3946. (doi: 10.1158/1078-0432.CCR-20-0414)

Briggs, A., Daniele, B., Dick, K., Evans, T. R. J., Galle, P. R., Hubner, R. A., Lopez, C., Siebert, U., Tremblay, G. (2020) Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinoma. British Journal of Cancer, 122, pp. 1754-1759. (doi: 10.1038/s41416-020-0817-7)

Corrie, P.G. et al. (2020) Scheduling nab-paclitaxel combined with gemcitabine as first line treatment for metastatic pancreatic adenocarcinoma. British Journal of Cancer, 122, pp. 1760-1768. (doi: 10.1038/s41416-020-0846-2)

Leung, E. Y.L., Ennis, D. P., Kennedy, P. R., Hansell, C., Dowson, S., Farquharson, M., Spiliopoulou, P., Nautiyal, J., McNamara, S., Carlin, L. M., Fisher, K., Davis, D. M., Graham, G., McNeish, I. A. (2020) NK cells augment oncolytic adenovirus cytotoxicity in ovarian cancer. Molecular Therapy - Oncolytics, 16, pp. 289-301. (doi: 10.1016/j.omto.2020.02.001)

Alsina, A., Kudo, M., Vogel, A., Cheng, A.-L., Tak, W. Y., Ryoo, B.-Y., Evans, T. R. J., López López, C., Daniele, B., Misir, S., Ren, M., Izumi, N., Qin, S., Finn, R. S. (2020) Effects of subsequent systemic anticancer medication following first-line lenvatinib: a post hoc responder analysis from the phase 3 REFLECT study in unresectable hepatocellular carcinoma. Liver Cancer, 9, pp. 93-104. (doi: 10.1159/000504624)

Cebon, J. S. et al. (2020) Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma. Journal for ImmunoTherapy of Cancer, 8, (doi: 10.1136/jitc-2019-000410)

MacPherson, I. R., Spiliopoulou, P., Rafii, S., Saggese, M., Baird, R. D., Garcia-Corbacho, J., Italiano, A., Bonneterre, J., Campone, M., Cresti, N., Posner, J., Takeda, Y., Arimura, A., Spicer, J. (2019) A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer. Breast Cancer Research, 22, (doi: 10.1186/s13058-019-1178-0)

Naumann, R. W., Hollebecque, A., Meyer, T., Devlin, M.-J., Oaknin, A., Kerger, J., López-Picazo, J. M., Machiels, J.-P., Delord, J.-P., Evans, T. R.J., Boni, V., Calvo, E., Topalian, S. L., Chen, T., Soumaoro, I., Li, B., Gu, J., Zwirtes, R., Moore, K. N. (2019) Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: Results from the phase I/II CheckMate 358 trial. Journal of Clinical Oncology, 37, pp. 2825-2834. (doi: 10.1200/JCO.19.00739)

Jones, R. L. et al. (2019) Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours. European Journal of Cancer, 120, pp. 132-139. (doi: 10.1016/j.ejca.2019.07.024)

Evans, T. R. J., Kudo, M., Finn, R. S., Han, K.-H., Cheng, A.-L., Ikeda, M., Kraljevic, S., Ren, M., Ductus, C. E., Piscaglia, F., Sung, M. W. (2019) Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma. British Journal of Cancer, 121, pp. 218-221. (doi: 10.1038/s41416-019-0506-6)

Reader, C. S., Vallath, S., Steele, C. W., Haider, S., Brentnall, A., Desai, A., Moore, K. M., Jamieson, N. B., Chang, D., Bailey, P., Scarpa, A., Lawlor, R., Chelala, C., Keyse, S. M., Biankin, A., Morton, J. P., Evans, T.R. J., Barry, S. T., Sansom, O. J., Kocher, H. M., Marshall, J. F. (2019) The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. Journal of Pathology, 249, pp. 332-342. (doi: 10.1002/path.5320)

Neves, K. B., Rios, F. J., Jones, R., Evans, T. R. J., Montezano, A. C., Touyz, R. M. (2019) Microparticles from vascular endothelial growth factor pathway inhibitor-treated cancer patients mediate endothelial cell injury. Cardiovascular Research, 115, pp. 978-988. (doi: 10.1093/cvr/cvz021)

Conway, J. R.W., Herrmann, D., Evans, T.R. J., Morton, J. P., Timpson, P. (2019) Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine. Gut, 68, pp. 742-758. (doi: 10.1136/gutjnl-2018-316822)

Twelves, C., Anthoney, A., Savulsky, C. I., Guo, M., Reyderman, L., Cresti, N., Semiglazov, V., Timcheva, C., Zubairi, I., Morrison, R., Plummer, R., Evans, T.R. J. (2019) A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine. British Journal of Cancer, 120, pp. 579-586. (doi: 10.1038/s41416-018-0366-5)

Anderson, R. L., Balasas, T., Callaghan, J., Coombes, R. C., Evans, J., Hall, J. A., Kinrade, S., Jones, D., Jones, P. S., Jones, R., Marshall, J. F., Panico, M. B., Shaw, J. A., Steeg, P. S., Sullivan, M., Tong, W., Westwell, A. D., Ritchie, J. W.A. (2019) A framework for the development of effective anti-metastatic agents. Nature Reviews Clinical Oncology, 16, pp. 185-204. (doi: 10.1038/s41571-018-0134-8)

Evans, T.R. J., Dean, E., Molife, L. R., Lopez, J., Ranson, M., El-Khouly, F., Zubairi, I., Savulsky, C., Reyderman, L., Jia, Y., Sweeting, L., Greystroke, A., Barriuso, J., Kristeleit, R. (2019) Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours. British Journal of Cancer, (doi: 10.1038/s41416-019-0377-x)

Fleming, K., McGuinness, J., Kipgen, D., Glen, H., Spiliopoulou, P. (2018) A case of Lenvatinib-induced Focal Segmental Glomerulosclerosis (FSGS) in metastatic medullary thyroid cancer. Case Reports in Oncological Medicine, 2018, (doi: 10.1155/2018/6927639)

Janjigian, Y. Y., Bendell, J., Calvo, E., Kim, J. W., Ascierto, P. A., Sharma, P., Ott, P. A., Peltola, K., Jaeger, D., Evans, J., de Braud, F., Chau, I., Harbison, C. T., Dorange, C., Tschaika, M., Le, D. T. (2018) CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. Journal of Clinical Oncology, 36, pp. 2836-2844. (doi: 10.1200/JCO.2017.76.6212)

Rust, K., Spiliopoulou, P., Tang, C. Y., Bell, C., Stirling, D., Phang, T. h. F., Davidson, R., Mackean, M., Nussey, F., Glasspool, R., Reed, N., Sadozye, A., Porteous, M., McGoldrick, T., Ferguson, M., Miedzybrodzka, Z., Mcneish, I., Gourley, C. (2018) Routine germline BRCA1 and BRCA2 testing in ovarian carcinoma patients: analysis of the Scottish real life experience. BJOG: An International Journal of Obstetrics and Gynaecology, 125, pp. 1451-1458. (doi: 10.1111/1471-0528.15171)

Lindsay, C. R. et al. (2018) Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme. ESMO Open, 3, (doi: 10.1136/esmoopen-2018-000408)

Basu, B. et al. (2018) Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer. Annals of Oncology, 29, pp. 1918-1925. (doi: 10.1093/annonc/mdy245)

Krol, I., Castro-Giner, F., Maurer, M., Gkountela, S., Szczerba, B., Scherrer, R., Coleman, N., Carreira, S., Bachmann, F., Anderson, S., Engelhardt, M., Lane, H., Evans, T. R. J., Plummer, R., Kristeleit, R., Lopez, J., Aceto, N. (2018) Detection of circulating tumor cell clusters in human glioblastoma. British Journal of Cancer, 119, pp. 487-491. (doi: 10.1038/s41416-018-0186-7)

Baxter, M.A., Glen, H., Evans, T.R.J. (2018) Lenvatinib and its use in the treatment of unresectable hepatocellular carcinoma. Future Oncology, 14, pp. 2021-2029. (doi: 10.2217/fon-2017-0689)

Candido, J. B. et al. (2018) CSF1R+ macrophages sustain pancreatic tumor growth through T cell suppression and maintenance of key gene programs that define the squamous subtype. Cell Reports, 23, pp. 1448-1460. (doi: 10.1016/j.celrep.2018.03.131)

Convertino, M., Church, T. R., Olsen, G. W., Liu, Y., Doyle, E., Elcombe, C. R., Barnett, A. L., Samuel, L. M., MacPherson, I. R., Evans, T. R.J. (2018) Stochastic pharmacokinetic-pharmacodynamic modeling for assessing the systemic health risk of perfluorooctanoate (PFOA) Toxicological Sciences, 163, pp. 293-306. (doi: 10.1093/toxsci/kfy035)

Carvajal, R. D. et al. (2018) Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: a phase III, multicentre, randomised trial (SUMIT) Journal of Clinical Oncology, 36, pp. 1232-1239. (doi: 10.1200/JCO.2017.74.1090)

Kudo, M., Finn, R., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., Blanc, J. F., Vogel, A., Komov, D., Evans, J., Lopez, C., Dutcus, C., Guo, M., Saito, K., Kraljevic, S., Tamai, T., Ren, M., Cheng, A.-L. (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet, 391, pp. 1163-1173. (doi: 10.1016/S0140-6736(18)30207-1)

Marchetti, C., Zyner, K. G., Ohnmacht, S. A., Robson, M., Haider, S. M., Morton, J. P., Marsico, G., Vo, T., Laughlin-Toth, S., Ahmed, A. A., Di Vita, G., Pazitna, I., Gunaratnam, M., Besser, R. J., Andrade, A. C.G., Diocou, S., Pike, J. A., Tannahill, D., Pedley, R. B., Evans, T.R. J., Wilson, W. D., Balasubramanian, S., Neidle, S. (2018) Targeting multiple effector pathways in pancreatic ductal adenocarcinoma with a G-quadruplex-binding small molecule. Journal of Medicinal Chemistry, 61, pp. 2500-2517. (doi: 10.1021/acs.jmedchem.7b01781)

Cook, N., Basu, B., Smith, D.-M., Gopinathan, A., Evans, T.R. J., Steward, W. P., Palmer, D., Propper, D., Venugopal, B., Hategan, M., Anthoney, D. A., Hampson, L. V., Nebozhyn, M., Tuveson, D., Farmer-Hall, H., Turner, H., McLeod, R., Halford, S., Jodrell, D. (2018) A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. British Journal of Cancer, 118, pp. 793-801. (doi: 10.1038/bjc.2017.495)

Wilson, R. A.M., Evans, T.R. J., Fraser, A. R., Nibbs, R. J.B. (2018) Immune checkpoint inhibitors: new strategies to checkmate cancer. Clinical and Experimental Immunology, 191, pp. 133-148. (doi: 10.1111/cei.13081)

Graham, J., Spiliopoulou, P., Arbuckle, R., Bridge, J. A., Cassidy, J. (2017) A pilot study of subjective well-being in colorectal cancer patients and their caregivers. Patient Related Outcome Measures, 8, pp. 111-119. (doi: 10.2147/PROM.S141815)

Meyer, T., Fox, R., Ma, Y. T., Ross, P. J., James, M. W., Sturgess, R., Stubbs, C., Stocken, D. D., Wall, L., Watkinson, A., Hacking, N., Evans, T.R. J., Collins, P., Hubner, R. A., Cunningham, D., Primrose, J. N., Johnson, P. J., Palmer, D. H. (2017) Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterology and Hepatology, 2, pp. 565-575. (doi: 10.1016/S2468-1253(17)30156-5)

de la Cruz-Merino, L., Di Guardo, L., Grob, J.-J., Venosa, A., Larkin, J., McArthur, G. A., Ribas, A., Acierto, P. A., Evans, J. T.R., Gomez‑Escobar, A., Barteselli, G., Eng, S., Hsu, J. J., Uyei, A., Dréno, B. (2017) Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study. Journal of Translational Medicine, 15, (doi: 10.1186/s12967-017-1246-0)

Vennin, C. et al. (2017) Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. Science Translational Medicine, 9, (doi: 10.1126/scitranslmed.aai8504)

Wilson, R. H., Evans, T.R. J., Middleton, M. R., Molife, L. R., Spicer, J., Dieras, V., Roxburgh, P., Giordano, H., Jaw-Tsai, S., Goble, S., Plummer, R. (2017) A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. British Journal of Cancer, 116, (doi: 10.1038/bjc.2017.36)

Evans, T.R.J., Van Cutsem, E., Moore, M.J., Bazin, I.S., Rosemurgy, A., Bodoky, G., Deplanque, G., Harrison, M., Melichar, B., Pezet, D., Elekes, A., Rock, E., Lin, C., Strauss, L., O'Dwyer, P.J. (2017) Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer. Annals of Oncology, 28, pp. 354-361. (doi: 10.1093/annonc/mdw607)

Soria, J.C., Gan, H.K., Blagden, S.P., Plummer, R., Arkenau, H.T., Ranson, M., Evans, T.R.J., Zalcman, G., Bahleda, R., Hollebecque, A., Lemech, C., Dean, E., Brown, J., Gibson, D., Peddareddigari, V., Murray, S., Nebot, N., Mazumdar, J., Swartz, L., Auger, K.R., Fleming, R.A., Singh, R., Millward, M. (2016) A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors. Annals of Oncology, 27, pp. 2268-2274. (doi: 10.1093/annonc/mdw427)

Driscoll, D. R., Karim, S. A., Sano, M., Gay, D. M., Jacob, W., Yu, J., Mizukami, Y., Gopinathan, A., Jodrell, D. I., Evans, T.R. J., Bardeesy, N., Hall, M. N., Quattrochi, B. J., Klimstra, D. S., Barry, S. T., Sansom, O. J., Lewis, B. C., Morton, J. P. (2016) mTORC2 signaling drives the development and progression of pancreatic cancer. Cancer Research, 76, pp. 6911-6923. (doi: 10.1158/0008-5472.CAN-16-0810)

Edeline, J., Blanc, J.-F., Johnson, P., Campillo-Gimenez, B., Ross, P., Ma, Y. T., King, J., Hubner, R. A., Sumpter, K., Darby, S., Evans, J., Iwuji, C., Swinson, D., Collins, P., Patel, K., Muazzam, I., Palmer, D. H., Meyer, T. (2016) A multicenter comparison between Child Pugh and ALBI scores in patients treated with sorafenib for hepatocellular carcinoma. Liver International, 36, pp. 1821-1828. (doi: 10.1111/liv.13170)

Jamieson, D., Griffin, M. J., Sludden, J., Drew, Y., Cresti, N., Swales, K., Merriman, M., Allen, R., Bevan, P., Buerkle, M., Mala, C., Coyle, V., Rodgers, L., Dean, E., Greystoke, A., Banerji, U., Wilson, R. H., Evans, T.R. J., Anthoney, A., Ranson, M., Boddy, A. V., Plummer, R. (2016) A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours. European Journal of Cancer, 68, pp. 1-10. (doi: 10.1016/j.ejca.2016.08.026)

Sharma, P., Callahan, M. K., Bono, P., Kim, J., Spiliopoulou, P., Calvo, E., Pillai, R. N., Ott, P. A., de Braud, F., Morse, M., Le, D. T., Jaeger, D., Chan, E., Harbison, C., Lin, C.-S., Tschaika, M., Azrilevich, A., Rosenberg, J. E. (2016) Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncology, 17, pp. 1590-1598. (doi: 10.1016/S1470-2045(16)30496-X)

Propper, D., Jones, K., Anthoney, D. A., Mansoor, W., Ford, D., Eatock, M., Agarwal, R., Inatani, M., Saito, M., Evans, T.R. J. (2016) Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma. BMC Cancer, 16, (doi: 10.1186/s12885-016-2828-6)

Zhu, A. X., Kang, Y.-K., Rosmorduc, O., Evans, T.R. J., Santoro, A., Ross, P., Gane, E., Vogel, A., Jeffers, M., Meinhardt, G., Peña, C. E.A. (2016) Biomarker analyses of clinical outcomes in patients with advanced hepatocellular carcinoma treated with Sorafenib with or without Erlotinib in the SEARCH Trial. Clinical Cancer Research, 22, pp. 4870-4879. (doi: 10.1158/1078-0432.CCR-15-2883)

Aparicio, T., Zaanan, A., Mary, F., Afchain, P., Manfredi, S., Evans, T. R. J. (2016) Small bowel adenocarcinoma. Gastroenterology Clinics of North America, 45, pp. 447-457. (doi: 10.1016/j.gtc.2016.04.004)

Bilsland, A. E., Spiliopoulou, P., Evans, T.R. J. (2016) Virotherapy: cancer gene therapy at last? F1000Research, 5, (doi: 10.12688/f1000research.8211.1)

Antonia, S. J., López-Martin, J. A., Bendell, J., Ott, P. A., Taylor, M., Eder, J. P., Jäger, D., Pietanza, M. C., Le, D. T., de Braud, F., Morse, M. A., Ascierto, P. A., Horn, L., Amin, A., Pillai, R. N., Evans, J., Chau, I., Bono, P., Atmaca, A., Sharma, P., Harbison, C. T., Lin, C.-S., Christensen, O., Calvo, E. (2016) Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncology, 17, pp. 883-895. (doi: 10.1016/S1470-2045(16)30098-5)

Steele, C. W. et al. (2016) CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer Cell, 29, pp. 832-845. (doi: 10.1016/j.ccell.2016.04.014)

Milojkovic Kerklaan, B., Slater, S., Flynn, M., Greystoke, A., Witteveen, P. O., Megui-Roelvink, M., de Vos, F., Dean, E., Reyderman, L., Ottesen, L., Ranson, M., Lolkema, M. P. J., Plummer, R., Kristeleit, R., Evans, T. R. J., Schellens, J. H. M. (2016) A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors. Investigational New Drugs, 34, pp. 329-337. (doi: 10.1007/s10637-016-0344-9)

Spiliopoulou, P., Bowers, S. P., Gibson, S., White, J., Reed, N. (2016) Three cases of thyroid cancer following the diagnosis of testicular cancer: treatment-related complication or genetics? Scottish Medical Journal, 61, pp. 111-116. (doi: 10.1177/0036933016635409)

Graham, J.S., Boyd, K., Coxon, F.Y., Wall, L.R., Eatock, M.M., Maughan, T.S., Highley, M., Soulis, E., Conway, F., Evans, T. (2016) A phase II study of capecitabine and oxalplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract. BMC Research Notes, 9, (doi: 10.1186/s13104-015-1778-4)

Erami Rud Majani, Z. et al. (2016) Intravital FRAP imaging using an E-cadherin-GFP mouse reveals disease- and drug-dependent dynamic regulation of cell-cell junctions in live tissue. Cell Reports, 14, pp. 152-167. (doi: 10.1016/j.celrep.2015.12.020)

Carotenuto, P. et al. (2016) Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers. Gut, 66, pp. 1268-1277. (doi: 10.1136/gutjnl-2016-312278)